We believe that new approaches are needed to address obesity and type 2 diabetes to break the pattern of chronic medications and free patients from the burden of these diseases. Our goal is to improve patients’ quality of life and prevent and reverse metabolic diseases by treating their root causes in the key metabolic control organs of the gut—the duodenum and the pancreas. Learn more about our science and our company at fractylhealth.com.
2010
Fractyl Health raised undisclosed on September 15, 2022
Investors: Taiwania Capital Management Corporation and + 8 Other investors